Drug intelligence / Profile preview

APL-103

Development stage: Preclinical
Lead developer: Apollomics
Modality: Small Molecules

Overview

APL-103 is an investigational small molecule inhibitor of the epidermal growth factor receptor (EGFR) being developed by Apollomics. It is designed to target and inhibit the tyrosine kinase activity of EGFR, a protein often overexpressed or mutated in various cancers, including non-small cell lung cancer and other solid tumors. By blocking EGFR signaling, APL-103 aims to suppress tumor cell proliferation and survival. The drug was part of the pipeline associated with CrownMab Biotech before being listed under Apollomics' oncology portfolio.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on APL-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APL-103.

Explore the full profile